Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

This is an open-label, single-center, non-randomized phase I/II pilot study evaluating proton-based Total Marrow Irradiation (TMI) as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult patients with high-risk or relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These patients have an unfavorable prognosis with standard conditioning approaches. Participants will receive a standard conditioning regimen consisting of either myeloablative or reduced-intensity chemotherapy, selected according to age an

Trial Details

NCT ID
NCT07532824
Phase
PHASE1 / PHASE2
Sponsor
Institute of Hematology and Blood Transfusion, Czech Republic
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Proton Total Marrow Irradiation
Locations (sample)
  • Prague, Czechia|50.08804,14.42076
  • Prague, Czechia|50.08804,14.42076

Key Eligibility Criteria

  • Underlying diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),
  • A) Acute Myeloid Leukemia (AML), meeting at least one of the following criteria:
  • i. Relapsed disease after a prior complete remission (CR) or
  • ii. Disease refractory to at least two cycles of intensive chemotherapy or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →